Harmful effects of NSAIDs among patients with hypertension and coronary artery disease

American Journal of Medicine

Volumn 124, Issue 7, 2011, Pages 614-620

  Bavry, Anthony A ^a   Khaliq, Asma ^a   Gong, Yan ^b   Handberg, Eileen M ^a   Cooper Dehoff, Rhonda M ^a,b   Pepine, Carl J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Coronary artery disease; Hypertension; Myocardial infarction; Nonsteroidal anti inflammatory drugs; NSAIDs

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; VERAPAMIL;

AGED; ARTICLE; BLOOD PRESSURE; CORONARY ARTERY DISEASE; DEATH; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; STROKE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CONFOUNDING FACTORS (EPIDEMIOLOGY); CORONARY ARTERY DISEASE; DICLOFENAC; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; IBUPROFEN; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NAPROXEN; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; SULFONAMIDES; VERAPAMIL;

EID: 79959336713     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2011.02.025     Document Type: Article

References (35)

1. C. Bombardier, L. Laine, and A. Reicin Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis VIGOR Study Group N Engl J Med 343 2000 1520 1528
2. R.S. Bresalier, R.S. Sandler, and H. Quan Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 2005 1092 1102 (Pubitemid 40365350)
3. S.D. Solomon, J.J. McMurray, and M.A. Pfeffer Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 352 2005 1071 1080 (Pubitemid 40365348)
4. P. Juni, L. Nartey, S. Reichenbach, R. Sterchi, P.A. Dieppe, and M. Egger Risk of cardiovascular events and rofecoxib: cumulative meta-analysis Lancet 364 2004 2021 2029 (Pubitemid 39593078)
5. S.D. Solomon, J. Wittes, and P.V. Finn Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis Circulation 117 2008 2104 2113 (Pubitemid 351572169)
6. P.M. Kearney, C. Baigent, J. Godwin, H. Halls, J.R. Emberson, and C. Patrono Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials BMJ 332 2006 1302 1308
7. E.M. Antman, J.S. Bennett, A. Daugherty, C. Furberg, H. Roberts, and K.A. Taubert Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association Circulation 115 2007 1634 1642 (Pubitemid 46648649)
8. J.C. Waksman, A. Brody, and S.D. Phillips Nonselective nonsteroidal antiinflammatory drugs and cardiovascular risk: are they safe? Ann Pharmacother 41 2007 1163 1173 (Pubitemid 47122553)
9. D.J. Graham, D. Campen, and R. Hui Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study Lancet 365 2005 475 481 (Pubitemid 40215729)
10. J. Hippisley-Cox, and C. Coupland Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis BMJ 330 2005 1366
11. E.L. Fosbol, F. Folke, and S. Jacobsen Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals Circ Cardiovasc Qual Outcomes 3 2010 395 405
12. P. McGettigan, and D. Henry Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 JAMA 296 2006 1633 1644 (Pubitemid 44511610)
13. S. Trelle, S. Reichenbach, and S. Wandel Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis BMJ 342 2011 c7086
14. B.K. Martin, C. Szekely, and J. Brandt Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib Arch Neurol 65 2008 896 905 (Pubitemid 352008472)
15. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
16. G.H. Gislason, S. Jacobsen, and J.N. Rasmussen Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction Circulation 113 2006 2906 2913 (Pubitemid 44297231)
17. T.M. MacDonald, and L. Wei Effect of ibuprofen on cardioprotective effect of aspirin Lancet 361 2003 573 574 (Pubitemid 36207477)
18. J.P. Curtis, Y. Wang, E.L. Portnay, F.A. Masoudi, E.P. Havranek, and H.M. Krumholz Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study BMJ 327 2003 1322 1323 (Pubitemid 37510454)
19. C.J. Pepine, E.M. Handberg, and R.M. Cooper-DeHoff A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial JAMA 290 2003 2805 2816 (Pubitemid 37509488)
20. M.C. Becker, T.H. Wang, and L. Wisniewski Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis Am Heart J 157 2009 606 612
21. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons Pharmacological management of persistent pain in older persons J Am Geriatr Soc 57 2009 1331 1346
22. A.G. Johnson, T.V. Nguyen, and R.O. Day Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis Ann Intern Med 121 1994 289 300
23. A. Morrison, D.R. Ramey, J. van Adelsberg, and D.J. Watson Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension Curr Med Res Opin 23 2007 2395 2404 (Pubitemid 350033441)
24. T. Kurth, R.J. Glynn, and A.M. Walker Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs Circulation 108 2003 1191 1195 (Pubitemid 37099986)
25. F. Catella-Lawson, M.P. Reilly, and S.C. Kapoor Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N Engl J Med 345 2001 1809 1817
26. M.L. Capone, M.G. Sciulli, and S. Tacconelli Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects J Am Coll Cardiol 45 2005 1295 1301 (Pubitemid 40523153)
27. M.M. Wolfe, D.R. Lichtenstein, and G. Singh Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs N Engl J Med 340 1999 1888 1899 (Pubitemid 29272670)
28. D.J. Bjorkman, and M.B. Kimmey Nonsteroidal anti-inflammatory drugs and gastrointestinal disease: pathophysiology, treatment and prevention Dig Dis 13 1995 119 129
29. A.T. Chan, J.E. Manson, and C.M. Albert Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events Circulation 113 2006 1578 1587 (Pubitemid 43739417)
30. N. Goodson Coronary artery disease and rheumatoid arthritis Curr Opin Rheumatol 14 2002 115 120 (Pubitemid 34185292)
31. G. Singh, J.D. Miller, F.H. Lee, D. Pettitt, and M.W. Russell Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey Am J Manag Care 8 2002 S383 S391
32. R.A. Puenpatom, and T.W. Victor Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data Postgrad Med 121 2009 9 20
33. M.T. Velasquez, and J.D. Katz Osteoarthritis: another component of metabolic syndrome? Metab Syndr Relat Disord 8 2010 295 305
34. S. Uretsky, F.H. Messerli, and S. Bangalore Obesity paradox in patients with hypertension and coronary artery disease Am J Med 120 2007 863 870 (Pubitemid 47451305)
35. T.Y. Wang, L.K. Newby, and A.Y. Chen Hypercholesterolemia paradox in relation to mortality in acute coronary syndrome Clin Cardiol 32 2009 E22 E28